NPPA: Ceiling price of scheduled formulations revised

The NPPA has revised/ increased the ceiling price of 883 scheduled formulations in compliance of the provisions of Drugs (Price Control) Order 2013.

The Authority conducted a meeting on 31.03.2020 noted with satisfaction that the supply disruption of APIs caused by COVID-19 outbreak is returning to normalcy and no unusual price fluctuations in price of inputs for medicines, amid COVID-19 outbreak has been reported. Thus, normal price revisions have been allowed.

The Wholesale Price Index increase has been based on the data published by Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry, Government of India. Increase in ceiling price is based on Wholesale Price Index (WPI) is 1.88468 percent.

The revision in ceiling price of formulations also includes the revision of ceiling price of cardiac stents also.

The revised prices will be applicable from 1st April 2020 and the detail of revised prices is available on NPPA’s website

  • Related Posts

    • Health
    • June 11, 2025
    • 300 views
    Doctors trialling ‘poo pills’ to flush out dangerous superbugs

    UK doctors are attempting to clear dangerous superbug infections using “poo pills” containing freeze-dried faeces. The stool samples come from healthy donors and are packed with good bacteria. Early data…

    • Health
    • May 26, 2025
    • 201 views
    Three Day IGHM fame Healthcare Conclave proved Mahakumbh of Who’s Who

    Integrated Global Healthcare Mission Forum (IGHM) honored domain’s Champions of Humanity New Delhi: It was a veritable Mahakumbh of Who’s Who of healthcare’s varied aspects namely Hospitals, Medtech, Pharmacy, Health…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

    Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

    HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

    HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

    ED raids three pharma units in Baddi, Nalagarh

    ED raids three pharma units in Baddi, Nalagarh

    Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

    Glenmark Pharma: FDA concludes inspection at US facility, issues five observations